لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Parker CC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Clarke NW; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Urology, Salford Royal Hospital, Salford, UK., Cook AD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Kynaston H; Division of Cancer and Genetics, Cardiff University Medical School, Cardiff, UK., Catton CN; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Cross WR; Department of Urology, St James's University Hospital, Leeds, UK., Petersen PM; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Persad RA; Department of Urology, Bristol Urological Institute, Bristol, UK., Saad F; Department of Urology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada., Bower LC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK., Logue J; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK., Payne H; The Prostate Centre, London, UK., Forcat S; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Goldstein C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Murphy C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Anderson J; Department of Clinical Oncology, St James's University Hospital, Leeds, UK., Barkati M; Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada., Bottomley DM; Department of Clinical Oncology, St James's University Hospital, Leeds, UK., Branagan J; Northampton General Hospital, Northampton, UK., Choudhury A; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK., Chung PWM; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada., Cogley L; Derriford Hospital, Plymouth, UK., Goh CL; Royal Surrey Hospital, Guildford, UK., Hoskin P; Division of Cancer Sciences, University of Manchester, Manchester, UK; Mount Vernon Cancer Centre, Northwood, UK., Khoo V; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Malone SC; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Masters L; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Morris SL; Guy's and St Thomas' NHS Foundation Trust, London, UK., Nabid A; Service de Radio-Oncologie, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada., Ong AD; Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada., Raman R; Kent Oncology Centre, Kent and Canterbury Hospital, Canterbury, UK., Tarver KL; Department of Oncology, Queen's Hospital, Romford, UK., Tree AC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Worlding J; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK., Wylie JP; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK., Zarkar AM; Department of Oncology, University Hospitals Birmingham, Birmingham, UK., Parulekar WR; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address: mrcctu.radicals@ucl.ac.uk.

مؤلفون مشاركون: RADICALS investigators

المصدر: Lancet (London, England) [Lancet] 2024 Jun 01; Vol. 403 (10442), pp. 2405-2415. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study; Comparative Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/radiotherapy , Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/drug therapy , Androgen Antagonists*/therapeutic use , Androgen Antagonists*/administration & dosage , Prostatectomy* , Tosyl Compounds*/therapeutic use , Tosyl Compounds*/administration & dosage , Anilides*/therapeutic use , Anilides*/administration & dosage , Nitriles*/therapeutic use , Nitriles*/administration & dosage, Humans ; Male ; Aged ; Middle Aged ; Oligopeptides/therapeutic use ; Oligopeptides/administration & dosage ; Gonadotropin-Releasing Hormone/agonists ; Combined Modality Therapy ; Prostate-Specific Antigen/blood

المؤلفون: Parker CC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Kynaston H; Division of Cancer and Genetics, Cardiff University Medical School, Cardiff, UK., Cook AD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Clarke NW; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Urology, Salford Royal Hospital, Salford, UK., Catton CN; Princess Margaret Cancer Centre, Toronto, ON, Canada., Cross WR; Department of Urology, St James's University Hospital, Leeds, UK., Petersen PM; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Persad RA; Department of Urology, Bristol Urological Institute, Bristol, UK., Pugh CA; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Saad F; Department of Urology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Logue J; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK., Payne H; The Prostate Centre, London, UK., Bower LC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK., Brawley C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Rauchenberger M; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Barkati M; Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Bottomley DM; Department of Clinical Oncology, St James's University Hospital, Leeds, UK., Brasso K; Department of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark., Chung HT; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada., Chung PWM; Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada., Conroy R; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Falconer A; Radiotherapy Department, Charing Cross Hospital, London, UK., Ford V; Royal Devon and Exeter University NHS Foundation Trust, Exeter, UK., Goh CL; Royal Surrey County Hospital, Guildford, UK., Heath CM; Department of Clinical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., James ND; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Kim-Sing C; Department of Radiation Oncology, BC Cancer-Vancouver, Vancouver, BC, Canada., Kodavatiganti R; Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Bangor, UK., Malone SC; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Morris SL; Guy's and St Thomas' NHS Foundation Trust, London, UK., Nabid A; Service de Radio-Oncologie, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada., Ong AD; Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada., Raman R; Kent Oncology Centre, Kent and Canterbury Hospital, Canterbury, UK., Rodda S; Bradford Teaching Hospitals, Bradford, UK., Wells P; Barts Cancer Centre, St Bartholomew's Hospital, London, UK., Worlding J; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK., Parulekar WR; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address: mrcctu.radicals@ucl.ac.uk.

مؤلفون مشاركون: RADICALS investigators

المصدر: Lancet (London, England) [Lancet] 2024 Jun 01; Vol. 403 (10442), pp. 2416-2425. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/radiotherapy , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/surgery , Androgen Antagonists*/therapeutic use , Androgen Antagonists*/administration & dosage , Prostatectomy* , Tosyl Compounds*/therapeutic use , Tosyl Compounds*/administration & dosage , Anilides*/therapeutic use , Anilides*/administration & dosage , Nitriles*/therapeutic use , Nitriles*/administration & dosage, Humans ; Male ; Aged ; Middle Aged ; Oligopeptides/administration & dosage ; Oligopeptides/therapeutic use ; Gonadotropin-Releasing Hormone/agonists ; Prostate-Specific Antigen/blood ; Combined Modality Therapy ; Drug Administration Schedule